Sesen Bio — Corporate Update (December 2019)
68 slides from Sesen Bio's corporate update, Dec 16, 2019
Slide 1: Regulatory Update December 16, 2019
Regulatory Update December 16, 2019 NASDAQ: SESN
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS We may not actually achieve the plans, intentions or expectations disclosed in our forward- looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expect
Slide 3: Our Path Forward Starts with the Patient Journey
BLOOD IN URINE OUR PATH FORWARD See PCP; therapeutic trial of antibiotics prescribed STARTS WITH THE Still see blood in urine See PATIENT JOURNEY blood in urine; try different antibiotic Confusion and concern on problem Begin tests Referred to Urologist Shock and st CT Scan emotional Preparing for 1
Slide 4: Sesen Bio: late-stage oncology company and management team
SESEN BIO A late-stage oncology company developing targeted fusion protein medicines OUR MISSION We are passionate in our commitment to save and improve the lives of patients OUR TEAM Talented, dedicated and experienced management Thomas Cannell, DVM Jeannick Cizeau, Ph.D. Erin Clark Monica Forbes P
Slide 5: IR Presentations: Frequent, Transparent and Informative
IR Presentations: Frequent, Transparent and Informative 2019 IR Events Presentation Date � Business Update January 3 � 4Q 2018 Business Update March 4 � 1Q 2019 Business Update May 13 � Regulatory Update June 10 � Canaccord Conference August 7 � H.C. Wainwright Conference September 10 � 3Q 2019 Busi
Slide 6: Financial Overview
Financial Overview Cash position • Ending cash and cash equivalents of $57.9M as of Sept 30, 2019 • Sufficient cash to fund key strategic priorities into 4Q 2020 Capital structure • 104.7 M shares of common stock outstanding as of Oct 31, 2019 • No preferred stock • 134 M fully diluted1 • No Debt 1F
Slide 7: Key Face-to-Face 2019 FDA Meetings
Key Face-to-Face 2019 FDA Meetings Four collaborative meetings with FDA successfully completed in 2019 May 20th Type C Meeting: FDA Accepts Analytical Comparability Plan to Support the BLA and Commercialization of Vicinium • No additional clinical trials deemed necessary at this time, subject to fin
Slide 8: December 4th FDA Meeting
December 4th FDA Meeting Ty p e B p r e -BLA meeting to discuss CMC Key Elements • Gained alignment with the FDA on the final content of the BLA • No further meetings have been requested by the FDA at this time • FDA clarified the requirements for the PPQ campaign for bulk drug substance and drug pr
Slide 9: Key Elements of December BLA Submission for Vicinium
Key Elements of December BLA Submission for Vicinium We initiated our BLA submission under Rolling Review on December 6th and believe this significantly de-risks the regulatory path to approval Module 1 Module 2 Module 3 Module 4 Module 5 � General corporate � Introduction to summary � Drug substanc
Slide 10: Clear Regulatory Path into a Pivotal 2020
Clear Regulatory Path into a Pivotal 2020 2019 Accomplishments FDA • Type C CMC Meeting (May 20, 2019) � • Type B Clinical pre-BLA Meeting (Jun 6, 2019) � • Type C Confirmatory Trial Meeting (Nov 4, 2019) � • Granted Small Business Exemption (Dec 2, 2019) � • Type B CMC pre-BLA Meeting (Dec 4, 2019)
Slide 11: Sesen Bio Corporate Summary
Sesen Bio Corporate Summary • 2019 was a year of tremendous progress and accomplishment • 2020 is poised to be a transformational year for Sesen Bio • There remains a huge unmet medical need for patients 11
Slide 12: Appendix - Table of Contents
Appendix - Table of Contents Section Slide number Patient Journey 13-14 Unmet Medical Need 15-21 Dual Mechanism of Action 22-25 Regulatory 26-30 Clinical Data 31-50 Commercial Opportunity 51-60 Manufacturing & Supply Chain 61-66 Intellectual Property 67-68 12
Slide 13: Appendix: Patient Journey
Appendix Patient Journey 13
Slide 14: Patient surveys show bladder cancer experience is among the poorest
Patient surveys have shown that the experience of those with bladder cancer is one of the poorest1 Key Drivers of Poor Patient Journey in Bladder Cancer vs. Average Experience Among 5 Most Common Cancers2 90 86 80 75 72 68 70 65 60 50 47 40 30 % of Patients Who HadWho Experience % Patients of 20 10
Slide 15: Appendix: Unmet Medical Need
Appendix Unmet Medical Need 15
Slide 16: Significant Unmet Medical Need in NMIBC
Significant Unmet Medical Need in NMIBC ~440,000 new cases each year globally1 Bladder cancer is the 6th most prevalent cancer in the US, of which 75%-85% is NMIBC2,3 Bladder cancer is the single most expensive ($4 billion/year) cancer to treat in the US 4 BCG SHORTAGE One of the worst patient exper
Slide 17: Only products ever approved by the FDA for NMIBC
Significant Unmet Medical Need in NMIBC Only 3 products have ever been approved by the FDA for NMIBC Product FDA Approval Additional Product Information Thiotepa 1959 Rarely used in current treatment regimens BCG* 1989 (Tice) Recommended first line treatment Valstar 1998 Used only when radical cyste
Slide 18: Carcinoma in situ: the most difficult form of NMIBC to treat
Carcinoma in situ: the most difficult form of NMIBC to treat Carcinoma in situ vs. Normal Bladder Lining: Clinical Trial Implications: • Field change disease often involving the entire bladder lining that is very difficult to treat • Failed on two or more courses of BCG, which is the gold standard f
Slide 19: Radical cystectomy remains recommended option after BCG failure
Radical cystectomy remains recommended treatment option after BCG failure 60-70% lifetime risk of cystectomy associated with NMIBC1 • Long, complex surgical procedure (10+ hours) • Significant rates of morbidity (30-60% within 90 days) and mortality (2-9% within 6 months)2 – 64% complication rate wi
Slide 20: Vicinium is cystectomy-sparing
Our Phase III data suggests Vicinium is cystectomy-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: A Hero Organ Radical Cystectomy: Life-Altering Surgery � Self-controlled storage organ in � Often a 10 hour or longer surgery the body � In women, removal of the ent
Slide 21: Latest global BCG shortage expected to last through 2020
Latest global BCG shortage expected to last through 2020 2012 2013 2014 2015 2016 2017 2018 2019 Sanofi suspends production Merck announces shortages Sanofi discontinues all global Merck announces supply of BCG Connaught strain of BCG Tice strain production of BCG constraints of BCG Tice strain duri
Slide 22: Appendix: Dual Mechanism of Action
Appendix Dual Mechanism of Action 22
Slide 23: Vicinium is Highly Differentiated with Dual Mechanism of Action
Vicinium is Highly Differentiated and has a Dual Mechanism of Action • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets cancer cells while generally sparing healthy cells • Inhibits pr
Slide 24: Vicinium: Dual Mechanism of Action
Vicinium: Dual Mechanism of Action Mechanism 1: Exotoxin A Payload Kills cell directly Non-cleavable Ligand-checkpoint peptide Linker Vicinium interaction deactivates Antibody Fragment anti-tumor response Checkpoint Vicinium selectively Vicinium does not induce expression T cells recognize targets E
Slide 25: High somatic mutation rate in bladder cancer
The high somatic mutation rate in bladder cancer may lead to a better response to agents such as Vicinium that may stimulate T cell-mediated immune activation driven by neoantigens 25 Adapted from Zahir et al. Nature Medicine, 2017
Slide 26: Appendix: Regulatory
Appendix Regulatory 26
Slide 27: Long-term relationship with the agency shaped our program
Our long-term relationship with the agency has allowed us to shape our nonclinical and clinical program in alignment with FDA guidance 2018 FDA Guidance Vicinium Clinical Program • Conduct nonclinical studies to assess toxicity in animal models � • Conduct nonclinical studies to demonstrate anti-tum
Slide 28: Strong benefit-risk profile in Phase III Trial
Vicinium demonstrates a strong benefit-risk profile in our Phase III Trial Efficacy Surrogate Time to Health Endpoints Cystectomy Outcomes Benefit Risk : Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkp
Slide 29: Initiation of BLA submission under Rolling Review
Initiation of BLA submission under Rolling Review on December 6, 2019 Oncology Products Reviewed by FDA 2006 - 2015 Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Phase III 33% Products with BLA Submission 82% As part of a comprehensive
Slide 30: November 4th Type C FDA meeting
November 4th Type C FDA meeting We were successful in gaining alignment with the FDA on the design of our post-marketing confirmatory trial for Vicinium Key Elements The confirmatory trial will enroll BCG-refractory patients who received less-than-adequate BCG* • This represents a broader patient po
Slide 31: Appendix: Clinical Data
Appendix Clinical Data 31
Slide 32: Phase III Trial: Patient Demographics
PIII Phase III Trial: Patient Demographics All Cohorts COHORT 1 COHORT 2 COHORT 3 CHARACTERISTICS CIS that was refractory or CIS that recurred >6 Papillary tumors (without recurred within 6 months months but ≤11 months of CIS) that were refractory of adequate BCG adequate BCG or recurred within 6 mo
Slide 33: Phase III Clinical Data Set in NMIBC
Compelling Phase III Clinical Data Set in NMIBC Efficacy at 3 months • CIS: 40% complete response rate • Papillary: 71% recurrence-free rate Durable Efficacy • CIS: 52% of CIS patients who had a complete response at 3 months remained disease-free for a total of 12 months after starting treatment • P
Slide 34: Totality of Phase III data suggest strong benefit-risk profile
PIII We believe the totality of Phase III data suggest a strong benefit-risk profile All Cohorts Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) • 40% CRR at 3 months Defined as the proportion of patients who show no evidence of high-risk Primary Endpoint • Lower bound of 95%
Slide 35: Additional Vicinium Clinical Data CIS Patients
PII & PIII Additional Vicinium Clinical Data CIS Patients Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-mon
Slide 36: Evaluable Patient Data Tables by Cohort for CIS
PIII Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ CIS patients Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 1
Slide 37: Complete Response Rate: CIS Patients
PIII Complete Response Rate: We believe our 95% confidence interval rules out CIS Patients the CRR for Valstar and a clinically unmeaningful CRR Complete Response Rate 40% Legend: 39% 35% 95% CI 30% 28% Vicinium 25% 26% Duration of Response for patients with a CR at 6 months: 1 20% 19% Valstar: 13.5
Slide 38: Comparative reference data from different clinical trials
PIII Comparative reference data from different clinical trials CIS Patients Vicinium Keytruda 3 month CRR 40%1 3 month CRR 41%2 12 month CRR 17%1 12 month CRR 20%2 Treatment-related Grade 3-5 AEs 4%1 Treatment-related Grade 3-5 AEs 13%3 Mode of Administration Intravesical Mode of Administration Intr
Slide 39: Complete and Partial Response in Phase II
Complete and Partial Response: In our Phase II clinical trial, 83% of PII patients had a complete or partial response CIS Patients 3-Month Response 40% of patients had a complete response Start of Treatment with 43% of patients had a partial response Vicinium 17% of patients had no response *Note: D
Slide 40: Duration of Response: 52% of CIS patients
Duration of Response: 52% of CIS patients who had a complete response at PIII 3 months remained disease-free for a total of 12 months after starting CIS Patients treatment Median Duration of Response is 287 days (95% CI, 154-NE* days) (9.4 months)** 100 KM Estimate 80 X Censored 95% CI 60 52% 39% 40
Slide 41: Duration of Response: longer response, higher probability of remaining cancer-free
Duration of Response: The longer you have a complete response, the PIII higher the probability of remaining cancer-free CIS Patients Probability of Maintaining Complete Response (CR) for at Each time point a CR is confirmed, the probability of Least One Additional Year* maintaining a CR increases 11
Slide 42: Duration of Response: patients treated with less BCG
Duration of Response: Vicinium is generally more efficacious in CIS patients PIII treated with less BCG CIS Patients The BCG shortage may cause a new normal wherein patients receive less BCG 100 Legend: 7-9 BCG instillations ≥10 BCG instillations 80 X Censored 60 Median 40 20 % of Patients % Patient
Slide 43: Time to Disease Recurrence: papillary patients
Time to Disease Recurrence: For high-risk papillary patients who were PIII Papillary treated with Vicinium, 50% are disease-free at 1 year Patients Median time to recurrence is 402 days per Kaplan-Meier estimate (13.2 months) 100 Legend: 80 KM Estimate X Censored Free - 95% CI 60 50% 40 37% % of Pat
Slide 44: Time to Cystectomy: all cohorts
Time to Cystectomy: >75% of patients remain cystectomy-free for at PIII All Cohorts least 2.5 years No patient on treatment progressed to metastatic disease 100 80 Free - 60 Median 40 Legend: KM Estimate 20 X Censored % Patients of Cystectomy 95% CI 0 0 3 6 9 12 15 18 21 24 27 30 33 Time on treatmen
Slide 45: Time to Cystectomy: Responders vs non-responders
Time to Cystectomy: Responders have an 88% probability of remaining PIII cystectomy-free 3 years after starting treatment All Cohorts The average responder remains cystectomy-free for 1,035 days vs 631 days for non-responders 100 Free Statistically significant difference for - 80 responders vs. non-
Slide 46: Time to Cystectomy: Responders have 88% probability cystectomy-free
Time to Cystectomy: Responders have an 88% probability of remaining PIII cystectomy-free 3 years after starting treatment All Cohorts 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. • The average responder remains cystectomy-free for 1,035 days
Slide 47: Key Survival Endpoints
Key Survival Endpoints: Early survival data are encouraging regarding PIII health outcomes for patients treated with Vicinium All Cohorts Progression-Free Survival Time Point (Evaluable Patients) Progression-Free Survival (95% CI) 6-months (52) 99% (97%-100%) 12-months (25) 96% (90%-100%) 18-months
Slide 48: Safety and Tolerability: Phase II and Phase III
Safety and Tolerability: Our Phase II and Phase III clinical trials are highly PII & PIII All Cohorts consistent for safety and tolerability Increased dosing and duration of exposure does not appear to lead to an increase in incidence or severity of AEs Phase II Phase III Category Tre a tm e n t-rel
Slide 49: Phase III Safety and Tolerability by age
Phase III Phase trial Safety and Tolerability: Mean (range8.1 0 AEs patients:for all Note: 2 Datacohortsfrom all1, of consist& patients (n=133). 3 - 54), Mean treatment Mean AEs/patient 10 0 2 4 6 8 No age No The The average patient in the VISTA trial was ~74 years old 9.0 - related AEs for all pati
Slide 50: Pipeline of Targeted Therapies
Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicinium in combination with checkpoint inhibitors. Vicinium in combination with AstraZeneca’s anti-PD-L1, Imfinzi (durvalumab), is being evaluated in a Phase 1 study run by the National Cancer Institute. We have defe
Slide 51: Appendix: Commercial Opportunity
Appendix Commercial Opportunity 51
Slide 52: Large Global Commercial Opportunity
Large Global Commercial Opportunity Compelling Physician Intent to Prescribe Data After reviewing the data, high-prescribing Substantial US opportunity and OUS potential of 2-3 times the US Urologists state they would prescribe Vicinium to Anticipated virtuous cycle of advocacy across physicians, pa
Slide 53: Virtuous Cycle: physicians, patients and payers
Virtuous Cycle: High possibility that all three key segments are advocates & take action Physicians (Ancillary HCPs) Patients Payers (Caregivers/ Encourage use of Vicinium before RC (Private/ families) public) Advocate for product reimbursement Sources: Sesen Bio internal market research: Patient Jo
Slide 54: Key drivers of physician intent to prescribe
Safety, MOA and efficacy are all key drivers in intent to prescribe for high- prescribing Urologists Physician Intent to Prescribe Key Drivers of Physician Intent to Prescribe After reviewing the data, high-prescribing Urologists state they would prescribe Vicinium to 10 8.8 9 8.6 8.5 8 Would 7 Pres
Slide 55: High-prescribing Urologists recognize value of Vicinium
High-prescribing Urologists recognize the significant value across safety, MOA and efficacy “This is another bladder intravesical treatment available with an even lower risk of side effects than BCG and has a greater ability to prevent recurrence.” Safety & Tolerability “…the fact that it is specifi
Slide 56: Vicinium has potential to provide continuity of care
Vicinium has the potential to provide continuity of care for patients with NMIBC Tre a tm e n t w ith Tre a tm e n t w ith >90% of high-prescribing Urologists state Tre a tm e n t P rotocol BCG Vicinium that Vicinium would be very easy to integrate into their practice.* Directed by Urologist 9% Admi
Slide 57: Addressable Market (US)
Addressable Market (US) Annual Volume ~80K1 Patients diagnosed with bladder cancer ~75% - 85% of bladder cancer diagnoses are NMIBC2 Patients diagnosed with NMIBC ~40% - 50% of NMIBCs are high-risk3 Patients with high-risk NMIBC: Papillary: ~80%2 CIS: ~20%2 ~50% - 90% of BCG treatments fail or disea
Slide 58: Pricing and Reimbursement (US)
Pricing and Reimbursement (US) Price Reference Payer Management Responses (Annual Cost)1 to Pricing2 100% $200K CI 3 Price Range of Checkpoint CI 2 Inhibitors (CIs) for CI 1 Urothelial Carcinoma $150K 50% Proportion Payers of Proportion $100K 0% $30 K $60 K $90 K $150 K $50K Unrestricted Coverage PA
Slide 59: OUS opportunity is 2-3 times larger than the US
We estimate the OUS opportunity for Vicinium is 2-3 times larger than the US Geography Est. Incidence Relative to U.S.1 Est. Price Relative to U.S.2 EU5 1.2 – 1.4 0.50 – 0.71 Japan 0.4 – 0.6 0.60 – 0.70 Rest of Europe 1.0 – 1.2 0.60 – 1.10 (Not including EU5) North America 0.1 – 0.3 0.55 – 0.70 (Not
Slide 60: Only ~1,500 Urologists account for bulk of NMIBC treatment
Only ~1,500 Urologists account for the bulk of NMIBC treatment and are concentrated in group practices allowing for a very efficient commercial model ~60% of Urology practices have ≥5 Urologists1 BCG Prescribers2 100% 90% 80% 70% 60% ~1,500 Urologists treat 75% of patients 50% % of Patients of % 40%
Slide 61: Appendix: Manufacturing & Supply Chain
Appendix Manufacturing & Supply Chain 61
Slide 62: Reliable and Inexpensive Manufacturing Process
Reliable and Inexpensive Manufacturing Process Vicinium is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-good
Slide 63: Reliable and Inexpensive Manufacturing Process
Reliable and Inexpensive Manufacturing Process 2000 L E. coli Production Bioreactor Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) Cell Bank Shake flask 5 Column Purification DP Fill Finish (7 mL @ 5mg/mL) 1: Q-Sepharose FF 2: Ni2+ IMAC
Slide 64: Experienced partners for global manufacturing and supply
We have experienced partners for the global manufacturing and supply of Vicinium � Licensed for commercial production of 8 approved products � 25+ years developing and manufacturing biologics � 310+ protein-based therapeutics in development and/or manufacturing � Proven track record with FDA and wor
Slide 65: Comparability Strategy accepted by the FDA
The Comparability Strategy for Vicinium has been accepted by the FDA* Guidance “If a manufacturer can provide assurance of comparability through analytical studies alone, nonclinical or clinical studies with the post-change product are not warranted.”1 Sesen’s analytical comparability plan is compri
Slide 66: Vicinium manufacturing is less complicated than ADCs
The Vicinium manufacturing process is much less complicated than that for ADCs Vicinium cGMP manufacturing process producing a single fusion protein � Inexpensive � Reliable � Simple (linear) QA QA Purification Release Fill/Finish Release Bioreactor (Generates Drug (Generates Drug Market Substance)
Slide 67: Appendix: Intellectual Property
Appendix Intellectual Property 67
Slide 68: Vicinium Patent Life
Vicinium Patent Life Pending Applications Dosing Strategies for Targeting EpCAM positive bladder cancer. If allowed, Stabilized Chimeric Immunoglobulins would expire in 2036 or later. (April 2020 - July 2020) US: 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 20